Saturday 7 November 2026 Export APVO’s income statement to Excel — free account

Aptevo Therapeutics Inc.

APVO Healthcare Biotechnology

Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million.

EPS: +96.5%
Free cash flow: +23.1%

Quarter to June 2026, against a year earlier

1.24 0.03 −2.36%

Follow APVO

Alert me

Market cap: $2.3M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 4/9
Altman Z: 256174.47
Beneish M: 3.69
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 2.30

Revenue ttm 12.99

Net income ttm (26.41)

Free cash flow ttm (25.34)

Net debt Q (9.80)

Valuation

P/E 0.00

Forward P/E (0.49)

Price / sales 0.11

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.25

Financial health

Current ratio Q 2.08

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q +28.62%

Operating income growth Q −3.49%

EPS, this year +80.47%

EPS, next year A +61.33%

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +58.56%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.35%

10-year low 10-year high

P/B against its own 10 years 5.46%

10-year low 10-year high

EV/FCF against its own 10 years 39.50%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	17	9	22	10
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	1	0	—	—
	19	11	23	11

	2023	2024	2025	Q'26
Payables	4	1	1	1
ST’ Debt	—	—	—	—
Other	1	1	—	—
	7	6	6	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	(26.64%)	(54.21%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(15.03%)	0.93%	(1.11%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −6.02 Actual −5.31

−1,815.45 −1,303.44 −791.43 −279.42 232.59

Q1 FY25 Miss −64.75

Q3 FY25 Miss −2.52

Q1 FY26 Miss −0.81

Q2 FY26 Beat +0.71

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q1 FY25	−1,514.39	−1,579.14	Miss by 64.75
Q3 FY25	−37.59	−40.11	Miss by 2.52
Q1 FY26	−5.60	−6.41	Miss by 0.81
Q2 FY26	−6.02	−5.31	Beat by 0.71
Q3 FY26	−3.72	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(6.41)	(5.31)	—	—	—
’25	(1.58k)	(151.08)	(40.11)	(5.94)	(87.27)
’24	(132.56k)	(22.27k)	(6.44k)	(3.22k)	(31.43k)
’23	223.92k	(706.20k)	(287.07k)	(66.53k)	(834.06k)
’22	(889.92k)	3.20m	(861.21k)	(0.94)	1.57
’21	(941.59k)	(1.00m)	(821.02k)	(1.25)	(6.07)
’20	510.99k	(2.10)	(1.21m)	(1.92)	(5.23)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	3	—	—	—	3
’21	2	3	3	4	12
’20	—	0	1	2	4
’19	7	7	9	9	32
’18	4	7	6	6	23
’17	2	4	6	3	15

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(5)	—	—	—
’25	(7)	(7)	(7)	(5)	(26)
’24	(7)	(6)	(5)	(6)	(24)
’23	5	(5)	(6)	(5)	(12)
’22	(5)	(3)	(7)	(6)	(21)
’21	(8)	(5)	(5)	(4)	(22)
’20	(11)	(5)	(7)	(6)	(29)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(5)	—	—	—
’25	(7)	(7)	(7)	(5)	(26)
’24	(7)	(6)	(5)	(6)	(24)
’23	5	(5)	(6)	(5)	(12)
’22	(5)	(3)	(7)	(6)	(21)
’21	(8)	(5)	(5)	(4)	(22)
’20	(11)	(5)	(7)	(6)	(29)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	10	15	23	32	4	12	3	—	—	—	13		(17.7%)	7	7	—	0.0%
	Gross margin, %	(24.86)	65.82	51.39	(6.89)	100.00	100.00	100.00	—	—	—	0.00		+124.9 pt	Powerpack Aptevo Therapeutics Inc.’s next three years, line by line Analysts expect revenue to grow 0.0% a year to 2028 — faster than the −17.7% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(140)	(56)	(54)	(43)	(31)	(29)	7	(19)	(24)	(26)	(26)		(17.0%)
	EBT margin, %	(1,397.93)	(381.31)	(232.75)	(132.82)	(717.64)	(239.25)	225.24	0.00	0.00	0.00	0.00		+1,397.9 pt
	Net income	(112)	7	(54)	(40)	(18)	(28)	8	(17)	(24)	(26)	(26)		(15.0%)
Per share, $
Per share, $	Revenue	0.49	0.69	1.03	11.12	1.27	2.62	0.61	0.00	0.00	0.00	0.00		n/m
	Earnings	(5.55)	0.33	(2.39)	(13.86)	(5.23)	(6.07)	1.57	(834,058.80)	(31,431.65)	(87.27)	(57.77)		+35.8%
	Cash flow	(1.82)	(1.95)	(2.29)	(14.53)	(8.65)	(4.62)	(4.12)	(561,916.17)	(29,731.25)	(81.12)	(21.18)		+52.5%
	Capex	(0.12)	(0.07)	(0.04)	(0.05)	(0.03)	(0.15)	(0.01)	0.00	0.00	0.00	0.00		n/m
	Free cash flow	(1.95)	(2.01)	(2.33)	(14.58)	(8.67)	(4.78)	(4.13)	(561,916.17)	(29,731.25)	(81.12)	(21.18)		+51.4%
	Book value	2.50	3.85	1.35	4.06	4.89	0.26	3.52	585,437.13	5,943.75	55.09	5.05		+41.0%
	Shares, m	20	21	23	3	3	5	5	0	0	0	1		(37.0%)
Valuation, ×
Valuation, ×	P/E	0.00	6.38	0.00	0.00	0.00	0.00	0.92	—	—	—	0.00		1.0
	P/S	41,578,223.25	56,728,401.70	10,164,405.30	483,499.54	5,460,128.21	1,759,124.90	527,133.51	—	—	—	0.11		16,671,559.5
	P/B	8,210,231.36	10,136,221.27	7,711,054.96	1,323,846.41	4,389,424.51	17,782,206.63	380,818.33	—	—	—	0.25		7,133,400.5
	EV/Sales	41,578,219.60	56,728,397.46	10,164,404.99	483,499.87	5,460,126.90	1,759,122.38	527,132.03	—	—	—	(0.37)		16,671,557.6
	EV/FCF	(10,543,976.30)	(19,349,036.65)	(4,474,642.73)	(368,558.40)	(2,476,980.64)	(965,663.29)	(323,341.18)	—	—	—	0.19		(5,500,314.2)
Cash, $m
Cash, $m	Operating cash flow	(37)	(42)	(51)	(42)	(29)	(22)	(21)	(12)	(24)	(26)	(25)		(4.0%)
	Capex	(3)	(1)	(1)	0	0	(1)	0	—	—	—	0		(52.5%)
	Free cash flow	(39)	(43)	(52)	(43)	(29)	(22)	(21)	(12)	(24)	(26)	(25)		(4.7%)
Balance, $m
Balance, $m	Working capital	52	77	31	(8)	33	18	19	12	4	17	6		(11.6%)
	Net debt	(37)	(62)	(11)	11	(17)	(31)	(19)	(17)	(9)	(22)	(10)		(5.7%)
	Shareholders’ equity	51	82	30	12	17	1	18	12	5	17	6		(11.2%)
Returns, %
Returns, %	ROA	(102.37)	6.68	(58.20)	(66.91)	(33.19)	(51.67)	17.68	(58.96)	(119.36)	(128.73)	(186.29)		(26.4) pt
	ROIC	(618.46)	(169.33)	(169.51)	(113.36)	0.00	0.00	0.00	0.00	0.00	0.00	0.00		+618.5 pt
	ROE	(161.53)	10.52	(95.50)	(191.48)	(124.84)	(319.56)	83.66	(115.32)	(284.28)	(248.81)	(446.89)		(87.3) pt
People
People	Employees	118	121	118	80	58	54	45	40	42	36	—		(12.4%)
	Revenue/emp, $m	0.08	0.12	0.20	0.41	0.07	0.23	0.07	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EOCN Eocene Ltd.	$2.6M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−67.74% (below 0%: shrinking)	0.00%	0.00%	Compare
BIORQ Biora Therapeutics, Inc.	$2.5M	— (loss-making)	— (loss-making)	+1,500.00% (above 0%: growing)	n/m	+20.72% (above 0%: growing)	100.00%	(50,709.38%)	Compare
CLDI Calidi Biotherapeutics, Inc.	$2.5M	— (loss-making)	—	—	n/m	+11.16% (above 0%: growing)	—	0.00%	Compare
WINT Windtree Therapeutics, Inc.	$2.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+1.12% (above 0%: growing)	0.00%	0.00%	Compare
VIVS VivoSim Labs, Inc.	$2.3M	— (loss-making)	— (loss-making)	−51.35% (below 0%: shrinking)	n/m	+17.87% (above 0%: growing)	100.00%	(15,327.78%)	Compare
HCWB HCW Biologics Inc.	$2.3M	— (loss-making)	— (loss-making)	+1,954.55% (above 0%: growing)	n/m	−20.84% (below 0%: shrinking)	(69.25%)	(2,335.03%)	Compare
APVO Aptevo Therapeutics Inc.	$2.3M	— (loss-making)	— (loss-making)	+28.62% (above 0%: growing)	n/m	+23.11% (above 0%: growing)	0.00%	0.00%
SLXN Silexion Therapeutics Corp	$2.2M	— (loss-making)	—	—	n/m	−16.63% (below 0%: shrinking)	—	0.00%	Compare
BRTX Biorestorative Therapies, Inc.	$2.1M	— (loss-making)	— (loss-making)	−7.20% (below 0%: shrinking)	n/m	−35.26% (below 0%: shrinking)	68.10%	(14,593.53%)	Compare
Median of peers	$2.3M	—	—	−29.27%	—	−7.76%	34.05%	(1,167.51%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 31 August 2026

Ownership

Directors and executive officers, together less than 1%

Niowave, Inc. 13.82%

Armistice Capital Master Fund Ltd 9.99%

Hudson Bay Master Fund Ltd. 9.99%

Sabby Volatility Warrant Master Fund, Ltd. 9.99%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Aptevo Therapeutics Inc. (APVO) Latest News

5 Nov

Impact 3 · 8:30 AM · ACCESS Newswire

Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML

27 Oct

Impact 4 · 6:33 AM · Zacks Small Cap Research

APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate

26 Oct

Impact 4 · 8:05 AM · ACCESS Newswire

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

14 Oct

Impact 3 · 8:46 AM · ACCESS Newswire

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

24 Sep

Impact 4 · 8:05 AM

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

3 Sep

Impact 4 · 10:19 AM · InvestorsHub

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Impact 4 · 8:05 AM

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

24 Aug

Impact 4 · 5:02 AM

APVO: Focusing on Three Key Areas of Development

14 Aug

Impact 3 · 8:05 AM

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

27 Jul

Impact 3 · 8:05 AM

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

30 Jun

Impact 3 · 8:05 AM

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

16 Jun

Impact 4 · 5:15 AM

APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement

27 May

Impact 4 · 8:05 AM · ACCESS Newswire

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

20 May

Impact 3 · 12:00 PM · Zacks

All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy

13 May

Impact 4 · 8:05 AM · ACCESS Newswire

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

6 May

Impact 5 · 8:05 AM · ACCESS Newswire

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

10 Apr

Impact 3 · 12:00 PM · Zacks

Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why

10 Mar

Impact 4 · 8:05 AM · ACCESS Newswire

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

3 Feb

Impact 4 · 8:05 AM · ACCESS Newswire

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

9 Jan

Impact 4 · 8:05 AM · ACCESS Newswire

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

26 Dec

Impact 3 · 8:05 AM · ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresInvestopediaMT NewswiresMT NewswiresMT Newswires

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

9 Dec

Impact 4 · 8:05 AM · ACCESS Newswire

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

19 Nov

Impact 3 · 9:55 AM · Zacks

Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

10 Nov

Impact 4 · 8:05 AM · ACCESS NewswireMT NewswiresClinical Trials ArenaMedical Device NetworkClinical Trials Arena

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

6 Nov

Impact 3 · 8:05 AM

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

8 Oct

Impact 3 · 8:20 AM · ACCESS Newswire

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

16 Sep

Impact 4 · 8:30 AM

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

4 Sep

Impact 4 · 8:45 AM · ACCESS Newswire

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

13 Aug

Impact 4 · 8:05 AM

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

11 Aug

Impact 3 · 8:05 AM

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Aptevo Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 31 August 2026

Ownership

Aptevo Therapeutics Inc. (APVO) Latest News

5 Nov

27 Oct

26 Oct

14 Oct

24 Sep

3 Sep

24 Aug

14 Aug

27 Jul

30 Jun

16 Jun

27 May

20 May

13 May

6 May

10 Apr

10 Mar

3 Feb

9 Jan

26 Dec

9 Dec

19 Nov

10 Nov

6 Nov

8 Oct

16 Sep

4 Sep

13 Aug

11 Aug

Stockrow Weekly